China Seeks Input on 59 Active Medical Device Registration Guidelines

Beijing, Sept 1, 2026 — China’s Center for Medical Device Evaluation (CMDE) released 59 draft registration and review guidelines for Class II active medical devices, opening a public comment period through Oct 8, 2026, as regulators standardize market entry requirements for powered equipment ranging from negative pressure suction devices to electronic diagnostic instruments.

Regulatory Snapshot

AttributeDetail
IssuerCenter for Medical Device Evaluation (CMDE), National Medical Products Administration
Document59 Guiding Principles for Registration and Review of Class II Active Medical Devices (Draft for Comments)
Lead guidelineNegative Pressure Source Suction Device Registration and Review Guiding Principles
Total guidelines59
Product classClass II active medical devices
Comment deadlineOct 8, 2026
SubmissionContact details per attached list

Key Scope

The batch covers registration and review technical standards for 59 categories of Class II active medical devices—equipment that relies on electrical energy or other power sources rather than human or gravitational force. The lead document addresses negative pressure source suction devices, with the full portfolio spanning diverse powered medical equipment categories.

Market Impact Analysis

The simultaneous release of 59 draft guidelines represents one of CMDE’s largest standardization efforts for mid-risk active devices, creating a comprehensive regulatory roadmap for manufacturers navigating China’s Class II registration pathway. For domestic and international device makers, the consolidated guidance reduces interpretive ambiguity during application preparation, potentially shortening registration timelines by clarifying technical documentation, clinical evidence, and testing requirements.

The Oct 8 comment deadline provides a five-week window for industry feedback, suggesting regulators aim to finalize the guidelines by year-end. The focus on Class II active devices—a category that includes infusion pumps, patient monitors, and therapeutic ultrasound equipment—signals intensified scrutiny of powered devices that pose moderate risk but are produced by a fragmented supplier base.

Forward-Looking Statement

Industry analysts expect the finalized 59 guidelines to take effect in early 2027, establishing the definitive regulatory baseline for Class II active device registrations through the remainder of the decade. Manufacturers with pending applications or pipeline products in the covered categories should review the drafts closely, as final versions may introduce new testing protocols or clinical data requirements not explicitly mandated under previous informal guidance. The bulk release approach suggests CMDE is moving toward systematic catalog-wide standardization rather than reactive, product-specific rulemaking, a shift that could accelerate overall review efficiency but demands proactive compliance monitoring across broad device portfolios.-China Health Reform Pulse

Policy Source: https://www.cmde.org.cn/flfg/zdyz/zqyjg/20260901134127123.html

Shanghai Opens TCM Procurement Alliance Listing for Fourth Batch

Shanghai, Aug 31, 2026 — Shanghai’s Medical Procurement Center opened the online application channel for the fourth batch and second-batch renewal of the National Traditional Chinese Medicine Patent Medicines and Simple Preparations Purchasing Alliance centralized procurement, requiring selected manufacturers to complete platform registration by Sept 15, 2026.

Policy Snapshot

AttributeDetail
IssuerShanghai Medical Centralized Bidding and Procurement Affairs Management Center
DocumentNotice on Launching Application and Networking for Fourth and Second Batch Renewal of National TCM Patent Medicines Purchasing Alliance
BatchesZCYLM-2026-1 (Fourth Batch); ZCYLM-2026-2 (Second Batch Renewal)
Application windowAug 31, 2026 – Sept 15, 2026
PlatformShanghai Medical Procurement Association portal (www.smpaa.cn)
ModuleBusiness Operations → My Drug Library
Listing typeNon-national centralized procurement related drugs
Sub-typeNational alliance centralized procurement, renewal drugs (selected channel)

Key Provisions

  • Mandatory filing — All drugs on Shanghai’s supply list for the two batches must be registered; previously listed selected drugs are exempt from re-application.
  • Digital workflow — Enterprises log into the procurement subsystem via the SMPAA portal, navigate to the drug library module, and select the designated listing categories to submit product information.
  • Supply lists — Two annexes detail the selected varieties: the fourth batch (ZCYLM-2026-1) and the second-batch renewal (ZCYLM-2026-2).

Market Impact Analysis

The 16-day application window creates a tight compliance timeline for TCM manufacturers seeking to maintain Shanghai market access under the national alliance procurement framework. By routing the fourth batch and renewal products through a dedicated “selected channel” within the non-national centralized procurement category, regulators are preserving the distinction between national volume-based procurement and alliance-level TCM procurement while streamlining the local listing process.

For pharmaceutical companies, failure to register by the Sept 15 deadline risks exclusion from Shanghai’s public hospital and community health center formularies, a significant volume channel in one of China’s wealthiest healthcare markets. The exemption for already-listed products reduces administrative duplication but requires manufacturers to verify their current platform status against the new supply lists.

Forward-Looking Statement

Industry analysts expect Shanghai’s listing template to be replicated across other alliance member provinces in September, as the national TCM procurement alliance synchronizes local platform onboarding ahead of the fourth-quarter procurement cycle. The second-batch renewal mechanism suggests the alliance is transitioning toward a rolling contract model for mature TCM products, potentially reducing annual re-tendering friction. Companies with selected TCM formulations should prioritize the Shanghai digital registration workflow, as delays in the initial listing phase could cascade into missed procurement windows across the alliance network. Final supply list confirmations are anticipated by late September 2026.-China Health Reform Pulse

Policy Source: https://www.smpaa.cn/xxgk/gggs/2026/08/31/24240.shtml

China Drafts Brain-Computer Interface Clinical Trials Guidelines

Beijing, Aug 28, 2026 — China’s Center for Medical Device Evaluation (CMDE) released draft technical review points for clinical trials of implantable brain-computer interface (BCI) systems with electronic device cursor interaction control functions, opening a public comment period through Sept 14 as regulators establish ground rules for one of neurotechnology’s most cutting-edge frontiers.

Regulatory Snapshot

AttributeDetail
IssuerCenter for Medical Device Evaluation (CMDE), National Medical Products Administration
DocumentTechnical Review Points for Clinical Trials of Implantable Brain-Computer Interface Systems (Electronic Device Cursor Interaction Control Function) (Draft for Comments)
Product scopeImplantable BCI systems enabling cursor interaction control via electronic devices
PurposeGuide registrants in preparing clinical trial application materials
Comment deadlineSept 14, 2026
ContactsJiang Yan, Wang Zehua
Emailwangzh@cmde.org.cn; jiangyan@cmde.org.cn
Phone010-86452521; 010-86452514

Technical Context

The draft guidelines address implantable BCI systems designed to translate neural signals into cursor movement commands, enabling paralyzed or motor-impaired patients to interact with computers and digital environments. The document is expected to cover trial design parameters including patient selection criteria, neural signal acquisition and decoding validation, safety monitoring for implant-related adverse events, and efficacy endpoints measuring cursor control accuracy and task completion rates.

Market Impact Analysis

The publication marks China’s first regulatory step toward formalizing clinical trial standards for consumer-facing implantable BCI applications, moving beyond experimental neurosurgical devices toward systems with broader assistive-technology potential. For neurotechnology developers, the draft provides critical clarity on evidentiary standards required to advance from preclinical studies to human trials, reducing regulatory uncertainty for domestic and international firms developing motor-prosthetic interfaces.

The cursor interaction control focus suggests CMDE is prioritizing BCI applications with clear functional outcomes—such as computer operation and environmental control—rather than open-ended neural research platforms. This targeted approach may accelerate trial timelines for assistive BCI devices while maintaining stricter scrutiny of more speculative applications.

The mid-September comment deadline signals regulators aim to finalize the guidance by late 2026, potentially clearing the path for China’s first implantable BCI clinical trials in early 2027. Companies with active neurotechnology programs, including those developing electrode arrays, signal processing algorithms, and wireless implantable systems, should use the comment window to align the draft with international standards from the U.S. FDA and EU notified bodies.

Forward-Looking Statement

Industry analysts expect the finalized guidelines to position China as a competitive jurisdiction for implantable BCI clinical development, potentially rivaling the U.S. and European Union in trial startup speed if the review process proves efficient. The cursor-control specificity may attract investment from assistive-technology and accessibility-focused ventures targeting China’s large population of patients with spinal cord injuries, amyotrophic lateral sclerosis, and stroke-related motor impairments. However, the implantable nature of the devices means safety requirements—particularly around long-term biocompatibility, infection risk, and signal degradation—will remain stringent. Companies are advised to prepare robust preclinical neurohistology and electromechanical reliability packages to support trial applications once the final guidance takes effect.-China Health Reform Pulse

Policy Source: https://www.cmde.org.cn/xwdt/zxyw/20260831102738147.html